圣地亚哥，2022年9月14日，媒体 / -Illumina，Inc。（纳斯达克股票代码：ILMN），这是DNA测序和基于阵列的技术的全球领导者，今天宣布已投资于六家基因组初创公司，用于第五家全球资金周期位于旧金山湾地区和英国剑桥的Illumina加速器Illumina Accelerator是一家世界一流的公司创建引擎，致力于与企业家合作，以建立突破性的基因组初创企业。该计划还于今天宣布了2022年10月1日的下一个资金周期申请截止日期。

"We are proud to welcome these six fantastic genomics startups to our Illumina Accelerator portfolio," said Amanda Cashin, co-founder and global head of Illumina for Startups. "We have an eight-year track record of partnering with talented entrepreneurs. We're proud of Illumina Accelerator's strong portfolio of 74 genomics startups focused on unlocking the power of the genome to improve human health around the world."

During six-month funding cycles twice per year, Illumina Accelerator provides the selected startups with access to seed investment, access to Illumina sequencing systems and reagents, and business guidance, genomics expertise, and fully operational lab space adjacent to Illumina's campuses in Cambridge or the Bay Area. Illumina Accelerator is accepting applications for the next funding cycle, which are due by October 1, 2022. Through a single process open to applicants from around the world, Illumina Accelerator will select up to five companies for each location. To learn more and apply, visit thewebsite.

加入Illumina Accelerator的基因组学创业公司投资组合的最新公司是：

• Acrobat Genomics Inc.是斯坦福大学的一项药物发现旋转，它通过利用其专有的高通量CRISPR基因编辑精度技术来建立新的治疗剂管道。
  
• Dama Health Ltd.是一家位于伦敦的妇女保健公司，提供精确筛查，以确定最合适的避孕类型和配方，赋予妇女权力，分配女性出生的人以及临床医生来做出个性化的生殖健康决策。
  
• Nusantics Pte. Ltd.是一家来自印度尼西亚的精确基因组学公司，开发和商业化了针对高度多样化的印尼和亚洲人口量身定制的与微生物组相关的诊断工具。
  
• Pandora Biosciences Inc.来自南非的一家神经科学公司，正在建立遗传多样性和生理相关的基于器官的疾病模型，以推动遗传复杂神经疾病的药物发现和发育。
  
• Terrapeutics Pharma Ltd., a drug discovery company based in Jerusalem, is tackling the most challenging "undruggable" drug targets by offering a new approach to discovering novel small therapeutic molecules from soil, based on the intelligence of nature.
  
• Viridian Seeds Inc., an agricultural biotechnology company from Cambridge, UK, and Galway, Ireland, is commercializing next-generation sustainable protein crops with novel traits to increase yield and reduce biotic and abiotic stress tolerances, while increasing protein and nutritional content for climate change mitigation, resilience, and food security.

"We are inspired by the global reach of genomics and by the vision these six startups have in advancing breakthrough discoveries in human health, agriculture, and sustainability," said Alex Aravanis, chief technology officer of Illumina. "We look forward to partnering with the new teams to accelerate their startups to the next level."

关于Illuminafor Startups

Illumina For Startups仅专注于通过与领先的风险投资者和企业家合作创建，启动和发展基因组学创业公司，为基因组学行业创造创新生态系统。Illumina for Startups倡议包括成立于2014年的Illumina Accelerator，以及由Illumina供电的红杉资本中国智能医疗基因组学孵化器，成立于2021年。IlluminaAccelerator是与Sanfrumina Research and Development Compoess Creation Colesent Illumina Research and Developtes Coperion Engerion Engine Engerion Coestion地区和英国剑桥。自成立以来，Illumina Accelerator投资了来自全球的74家基因组初创企业，这些初创公司统称为超过10亿美元的风险投资。大约93％的Illumina Accelerator投资已继续从领先的投资者那里筹集额外的资本。有关更多信息，请访问我们website.

关于Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visitillumina.com并与我们联系推特,Facebook,LinkedIn,Instagram， 和YouTube.

Investors:

Salli Schwartz
858-291-6421
IR@illumina.com

媒体：
Adi Raval
202-629-8172
pr@illumina.com